CatalystFDA/Bio

Ionis Pharmaceuticals falls after Pelacarsen fails key Phase 3 heart trial

Phase 3 failure directly impacts Ionis’s drug prospects, triggering negative market reaction.

What changed

Phase 3 failure directly impacts Ionis’s drug prospects, triggering negative market reaction.

Why it matters

Phase 3 failure directly impacts Ionis’s drug prospects, triggering negative market reaction. — impact context not separately stored; see What changed.

Sources

eodhd